Help
RSS
API
Feed
Maltego
Contact
Domain > www.monopartx.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2020-02-10
34.225.120.54
(
ClassC
)
2022-01-14
3.225.74.242
(
ClassC
)
2023-06-11
54.204.13.102
(
ClassC
)
2025-02-26
23.21.250.185
(
ClassC
)
2025-07-14
34.236.86.94
(
ClassC
)
2026-01-17
52.8.216.67
(
ClassC
)
Port 443
HTTP/1.1 200 OKDate: Sat, 17 Jan 2026 12:16:18 GMTServer: ApacheExpires: Thu, 19 Nov 1981 08:52:00 GMTCache-Control: no-store, no-cache, must-revalidate, post-check0, pre-check0Pragma: no-cacheVary: Accept-EncodingTransfer-Encoding: chunkedContent-Type: text/html; charsetUTF-8 !DOCTYPE html>!--if lt IE 7> html classno-js lt-ie9 lt-ie8 lt-ie7 langen> !endif-->!--if IE 7> html classno-js lt-ie9 lt-ie8 langen> !endif-->!--if IE 8> html classno-js lt-ie9 lt-ie10 langen> !endif-->!--if IE 8> html classno-js lt-ie10 langen> !endif-->!--if gt IE 9>!--> html classno-js langen> !--!endif-->head> !-- un-comment and delete 2nd meta below to disable zoom (not cool) meta nameviewport contentwidthdevice-width, minimum-scale1, maximum-scale1> --> meta nameviewport contentinitial-scale1.0, widthdevice-width> meta charsetUTF-8> title>Monopar Therapeutics Inc. (MNPR)/title> link relcanonical hrefhttps://www.monopartx.com> meta propertyog:site_name contentMonopar Therapeutics Inc.> meta propertyog:title contentMonopar Therapeutics Inc.> meta propertyog:type contentwebsite> meta propertyog:image contenthttps://d1io3yog0oux5.cloudfront.net/_70fd9f1ded729a9c8e504dca7e069527/monopartx/logo.png> meta propertyog:url contenthttps://www.monopartx.com> meta nameapple-mobile-web-app-capable contentno> meta nameapple-mobile-web-app-status-bar-style contentdefault> meta nameviewport contentwidthdevice-width, initial-scale1.0> meta nameapple-mobile-web-app-title contentMonopar Therapeutics> link relicon typeimage/png hrefhttps://d1io3yog0oux5.cloudfront.net/_70fd9f1ded729a9c8e504dca7e069527/monopartx/files/theme/images/favicons/favicon-32x32.png sizes32x32> link relicon typeimage/png hrefhttps://d1io3yog0oux5.cloudfront.net/_70fd9f1ded729a9c8e504dca7e069527/monopartx/files/theme/images/favicons/favicon-16x16.png sizes16x16> meta namemsapplication-TileColor content#da532c> meta nametheme-color content#ffffff> !-- RSS --> link relalternate typeapplication/rss+xml title# hrefindex.html# /> !-- Google Font --> link hrefhttps://fonts.googleapis.com/css?familyRubik:300,300i,400,400i,500,500i,700,700i,900,900i relstylesheet> !-- Primary CSS --> link relstylesheet typetext/css hrefhttps://d1io3yog0oux5.cloudfront.net/_70fd9f1ded729a9c8e504dca7e069527/monopartx/files/theme/site-files/20180202/_css/screen.min.css> link relstylesheet typetext/css hrefhttps://d1io3yog0oux5.cloudfront.net/_70fd9f1ded729a9c8e504dca7e069527/monopartx/files/theme/site-files/20180202/_css/mobile.min.css> !--if IE 9> link hrefhttps://d1io3yog0oux5.cloudfront.net/_70fd9f1ded729a9c8e504dca7e069527/monopartx/files/theme/site-files/20180202/_css/ie9.min.css mediascreen, projection relstylesheet typetext/css/> !endif--> !--if IE 9> style mediascreen> #footer, .header-holder { behavior: url(js/PIE/PIE.htc); } /style> !endif--> !--if lte IE 8> script typetext/javascript srcjs/html5shiv.js>/script> style mediascreen> /* uncomment for IE8 rounded corners #menu-main-nav .drop ul a, #menu-main-nav .drop, #menu-main-nav ul.sub-menu, #menu-main-nav .drop .c, #menu-main-nav li.parent, */ #footer, .header-holder, #horizontal_nav ul li, #horizontal_nav ul a, #tt-gallery-nav li, #tt-gallery-nav a, ul.tabset li, ul.tabset a, .karma-pages a, .karma-pages span, .wp-pagenavi a, .wp-pagenavi span, .post_date, .post_comments, .ka_button, .flex-control-paging li a, .colored_box, .tools, .karma_notify .opener, .callout_button, .testimonials { behavior: url(js/PIE/PIE.htc); } /style> !endif--> !--if IE> link relstylesheet hrefhttps://d1io3yog0oux5.cloudfront.net/_70fd9f1ded729a9c8e504dca7e069527/monopartx/files/theme/site-files/20180202/_css/ie.min.css mediascreen/> !endif--> !-- Global Site Tag (gtag.js) - Google Analytics --> script async srchttps://www.googletagmanager.com/gtag/js?idUA-106058307-1>/script> script> window.dataLayer window.dataLayer || ; function gtag(){dataLayer.push(arguments)}; gtag(js, new Date()); gtag(config, UA-106058307-1); /script> link relstylesheet hrefhttps://d1io3yog0oux5.cloudfront.net/_70fd9f1ded729a9c8e504dca7e069527/monopartx/files/theme/css/style.css> script> (function(i,s,o,g,r,a,m){iGoogleAnalyticsObjectr;irir||function(){ (ir.qir.q||).push(arguments)},ir.l1*new Date();as.createElement(o), ms.getElementsByTagName(o)0;a.async1;a.srcg;m.parentNode.insertBefore(a,m) })(window,document,script,https://www.google-analytics.com/analytics.js,ga); ga(create, UA-113253417-1, monopartx.com); (function() { var opts {}; var prefix /investors; if (location.hostname.indexOf(stockpr.com) 0) { opts.cookiePath location.pathname.substring(0, location.pathname.indexOf(/, 1) + 1) opts.page prefix + location.pathname.substring(location.pathname.indexOf(/, 1)); } else if (location.hostname.match(/^ir\./)) { opts.page prefix + location.pathname; } ga(send, pageview, opts); })(); /** * Function that tracks a click on an outbound link in Analytics. * This function takes a valid URL string as an argument, and uses that URL string * as the event label. Setting the transport method to beacon lets the hit be sent * using navigator.sendBeacon in browser that support it. */ var trackOutboundLink function(url,category) { if (!category) category outbound; ga(send, event, category, click, url, { transport: beacon }); } window.onload function() { // Add outbound link tracking in GA jq(a).not(.fancybox).each(function(){ var href jq(this).attr(href); if (typeof href undefined) return; if (href.indexOf(http) > 0 && ( href.indexOf(website_base_url) 0 && href.indexOf(ir_base_url) 0 && href.indexOf(eqcdn) 0 && href.indexOf(amazonaws) 0)) { jq(this).attr(onclick, trackOutboundLink( + href + )); }else { // Its not an outbound link, but if its a link to a file, we want to track that. if (href.match(/(\.pdf|\.jpg|\.png|\.gif|\.ppt|\.jpeg|\.mp3|\.mp4|\.wav|\.docx|\.doc|\.xsl|\.cslx)/g)) { jq(this).attr(onclick, trackOutboundLink( + href + , documents-and-files)); } } }); };/script>/head>body classpg-1 page-type-home pg-overview-overview home> div idloader-overlay>img srchttps://d1io3yog0oux5.cloudfront.net/_70fd9f1ded729a9c8e504dca7e069527/monopartx/files/theme/site-files/20180202/_img/loader.gif altLoading />/div> header>div classheader-bg> !--Topbar--> div classtopbar-info no-pad> div classcontainer> div classsocial-wrap-head col-md-2 no-pad> /div> /div> /div> !--Topbar-info-close--> div idheaderstic> div class top-bar container> div classrow> nav classnavbar navbar-default> div classcontainer-fluid> !-- Brand and toggle get grouped for better mobile display --> div classnavbar-header> button typebutton classnavbar-toggle icon-list-ul data-togglecollapse data-target#bs-example-navbar-collapse-1> span classsr-only>Toggle navigation/span> /button> a href/ aria-labelMonopar Therapeutics Inc.> div classlogo> /div> /a> /div> !-- Collect the nav links, forms, and other content for toggling --> div classcollapse navbar-collapse idbs-example-navbar-collapse-1> ul classnav navbar-nav navbar-right> li classdropdown>a href/pipeline classvisible-lg>Pipelineb classicon-angle-down>/b>/a>a href/pipeline classdropdown-toggle hidden-lg data-toggledropdown>Pipelineb classicon-angle-down>/b>/a> ul classdropdown-menu> li class >a href/pipeline/pipeline-chart>Pipeline Chart/a> /li> li classdropdown dropdown >a href/pipeline/alxn1840>ALXN1840/a> ul classdropdown-menu tier-three> li>a href/pipeline/alxn1840/easl-poster-may-2025 target_blank>EASL Poster May 2025/a>/li> li>a href/pipeline/alxn1840/ana-poster-september-2025 target_blank>ANA Poster September 2025/a>/li> li>a href/pipeline/alxn1840/ana-presentation-september-2025 target_blank>ANA Presentation September 2025/a>/li> li>a href/pipeline/alxn1840/aasld-presentation-november-2025 target_blank>AASLD Presentation November 2025/a>/li> /ul> /li> li class >a href/pipeline/uPAR-targeted-radiopharmaceuticals>uPAR-targeted radiopharmaceuticals/a> /li> li classdropdown dropdown >a href/pipeline/mnpr-101>MNPR-101/a> ul classdropdown-menu tier-three> li>a href/pipeline/mnpr-101/overview >Overview/a>/li> li>a href/pipeline/mnpr-101/development-strategy >Development Strategy/a>/li> li>a href/pipeline/mnpr-101/snmmi-poster-june-2024 target_blank>SNMMI Poster June 2024/a>/li> li>a href/pipeline/mnpr-101/eanm24-ppt target_blank>EANM Presentation October 2024/a>/li> /ul> /li> li classdropdown dropdown >a href/pipeline/collaborations>Collaborations/a> ul classdropdown-menu tier-three> li>a href/pipeline/collaborations/overview >Overview/a>/li> li>a href/pipeline/collaborations/current-collaborations >Current Collaborations/a>/li> /ul> /li> li classdropdown dropdown >a href/pipeline/publications>Publications/a> ul classdropdown-menu tier-three> li>a href/pipeline/publications/mnpr-101 >MNPR-101/a>/li> /ul> /li> /ul> /li> li classdropdown>a href/investors classvisible-lg>Investorsb classicon-angle-down>/b>/a>a href/investors classdropdown-toggle hidden-lg data-toggledropdown>Investorsb classicon-angle-down>/b>/a> ul classdropdown-menu> li class >a href/investors/_>Overview/a> /li> li class >a href/investors/annual-meeting>Annual Meeting/a> /li> li classdropdown dropdown >a href/investors/news-events>News / Events/a> ul classdropdown-menu tier-three> li>a href/investors/news-events/press-releases >Press Releases/a>/li> li>a href/investors/news-events/ir-calendar >IR Calendar/a>/li> li>a href/investors/news-events/in-the-news >In the News/a>/li> li>a href/investors/news-events/email-alerts >Email Alerts/a>/li> /ul> /li> li classdropdown dropdown >a href/investors/company-information>Company Information/a> ul classdropdown-menu tier-three> li>a href/investors/company-information/profile >Profile/a>/li> li>a href/investors/company-information/presentations >Presentations/a>/li> li>a href/investors/company-information/our-team >Our Team/a>/li> li>a href/investors/company-information/faq >FAQ/a>/li> /ul> /li> li classdropdown dropdown >a href/investors/stock-data>Stock Data/a> ul classdropdown-menu tier-three> li>a href/investors/stock-data/quote >Quote/a>/li> li>a href/investors/stock-data/charts >Charts/a>/li> li>a href/investors/stock-data/historical-data >Historical Data/a>/li> li>a href/investors/stock-data/analyst-coverage >Analyst Coverage/a>/li> /ul> /li> li classdropdown dropdown >a href/investors/sec-filings>SEC Filings/a> ul classdropdown-menu tier-three> li>a href/investors/sec-filings/all-sec-filings >All SEC Filings/a>/li> li>a href/investors/sec-filings/annual-reports >Annual Reports/a>/li> li>a href/investors/sec-filings/quarterly-reports >Quarterly Reports/a>/li> li>a href/investors/sec-filings/section-16-filings >Section 16 Filings/a>/li> /ul> /li> li classdropdown dropdown >a href/investors/corporate-governance>Corporate Governance/a> ul classdropdown-menu tier-three> li>a href/investors/corporate-governance/board-of-directors >Board of Directors/a>/li> li>a href/investors/corporate-governance/board-committees >Board Committees/a>/li> li>a href/investors/corporate-governance/governance-docs >Governance Documents/a>/li> /ul> /li> /ul> /li> li >a href/our-team classvisible-lg>Our Team/a>a href/our-team class hidden-lg >Our Team/a> /li> li >a href/careers classvisible-lg>Careers/a>a href/careers class hidden-lg >Careers/a> /li> li >a href/contact-us classvisible-lg>Contact Us/a>a href/contact-us class hidden-lg >Contact Us/a> /li> /ul> /div> !-- /.navbar-collapse --> /div> !-- /.container-fluid --> /nav> /div> /div> !--Topbar End--> /div>/div>/header>div classgrid wow fadeIn> div classeq-container> div classmodule-banner-slides> div classbanner-slides> div classbanner-slide overlay overlay--secondary dark stylebackground: url(https://d1io3yog0oux5.cloudfront.net/_70fd9f1ded729a9c8e504dca7e069527/monopartx/db/415/2922/image_resized_no_crop.png);background-position: 50% 50%;background-repeat: no-repeat;background-size: cover;background-color: #000;> div classcontainer> div classtext> div classrow> div classcol> h2>Personalized & Precise/h2> p classp1>Next generation targeted therapies for Wilson Disease and cancer/p> /div> /div> /div> /div> /div> /div> div classcontainer> div idslider-nav>/div> /div> /div> /div>/div> div classcomplete-content> div classcontainer idabout_us> div classrow js-same-height-row> div classcol-md-12 col-xs-12 col-sm-12 text-center no-pad heading-content wow fadeInUp animated animated data-wow-delay0.5s data-wow-offset200 stylevisibility: visible;-webkit-animation-delay: 0.5s; -moz-animation-delay: 0.5s; animation-delay: 0.5s;> div classcontent-headline> div idheading-title>Monopar Therapeutics/div> /div> p>Monopar Therapeutics is a clinical-stage biotechnology company developing novel radiopharmaceuticals for oncology and a new treatment for Wilson Disease, a rare genetic disorder. Its pipeline includes radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease. The radiopharma programs targeting advanced cancers include clinical-stage MNPR-101-Zr for imaging, and for therapy, clinical-stage MNPR-101-Lu and late-preclinical stage MNPR-101-Ac. Monopar builds its drug development pipeline through in-house efforts and licensing of late preclinical and clinical-stage therapeutics, leveraging its scientific and clinical expertise to reduce risk and accelerate development.br>br>Monopars team is located in Chicago, IL./p> /div> div classno-pad icon-boxes-1> !--Icon-box-start--> div classcol-sm-6 col-xs-12 col-md-6 col-lg-6> div classicon-box-3 wow fadeInUp js-same-height data-wow-delay0.6s data-wow-offset150> div classicon-boxwrap2> div classdna_icon icon-box-back2>/div> /div> div classicon-box2-title>Why Oncology?/div> p>Monopar is developing personalized and precise radiopharmaceuticals to diagnose and treat aggressive cancers./p> div classiconbox text-center> a rolebutton data-togglecollapse data-parent#clinicalPortfolio href#why-oncology aria-expandedfalse aria-controlswhy-oncology classcollapsed>i classfa fa-chevron-circle-down aria-hiddentrue>/i>/a> div idwhy-oncology classpanel-collapse collapse roletabpanel aria-expandedfalse styleheight: 0px;> div classhref panel-body data-href#> ul>li>Approximately one in every two individuals will develop cancer during their lifetime./li>li>Cancer is one of the leading causes of death worldwide and the second leading cause of death in the United States and Europe, accounting for nearly 1 in 4 deaths in the US./li>li>Just as no two people are the same, no two cancers are the same. We believe the future of cancer treatment will be personalized and precise./li>li>We see the emerging field of radiopharmaceuticals as transforming cancer care through its personalized and precise approach to treatment./li>/ul>a classbtn stylebackground: rgba(100, 24, 117, 0.8); display: inline-block; font-size: 12px; letter-spacing: 1px; font-weight: 300; line-height: 1; min-width: 100px; box-shadow: 0 4px #641775; margin-bottom: 5px; text-align: center; white-space: normal; -moz-transition: background-color 0.2s ease, border-color 0.2s ease; -o-transition: background-color 0.2s ease, border-color 0.2s ease; -webkit-transition: background-color 0.2s ease, border-color 0.2s ease; transition: background-color 0.2s ease, border-color 0.2s ease; border: none; color: #fff; margin: 0; padding: 10px 10px 7px 10px; border-radius: 0; text-decoration: none; font-family: Rubik, sans-serif; href/pipeline/uPAR-targeted-radiopharmaceuticals>MNPR-101-Zr, MNPR-101-Lu, & MNPR-101-Ac/a> /div> /div> /div> /div> /div> div classcol-sm-6 col-xs-12 col-md-6 col-lg-6> div classicon-box-3 wow fadeInUp js-same-height data-wow-delay0.6s data-wow-offset150> div classicon-boxwrap2> div classsearch_icon icon-box-back2>/div> /div> div classicon-box2-title>Why Rare Disease?/div> p>Monopar recently in-licensed bis-choline tetrathiomolybdate (ALXN1840), a late-stage investigational drug to treat Wilson Disease./p> div classiconbox text-center> a rolebutton data-togglecollapse data-parent#clinicalPortfolio href#why-rare-disease aria-expandedfalse aria-controlswhy-rare-disease classcollapsed>i classfa fa-chevron-circle-down aria-hiddentrue>/i>/a> div idwhy-rare-disease classpanel-collapse collapse roletabpanel aria-expandedfalse styleheight: 0px;> div classhref panel-body data-href#> ul>li>Our team consists of individuals with deep experience in rare diseases, including co-founding the successful orphan drug development companies BioMarin, Raptor Pharma, and Wilson Therapeutics./li>li>Our CEO has a long history with Wilson Disease, including a publication in Science on tetrathiomolybdate and helping launch a Wilson Disease focused company around what became known as ALXN1840./li>li>We share a passion for helping bring treatments to patients who often have limited options./li>/ul>a classbtn stylebackground: rgba(100, 24, 117, 0.8); display: inline-block; font-size: 12px; letter-spacing: 1px; font-weight: 300; line-height: 1; min-width: 100px; box-shadow: 0 4px #641775; margin-bottom: 5px; text-align: center; white-space: normal; -moz-transition: background-color 0.2s ease, border-color 0.2s ease; -o-transition: background-color 0.2s ease, border-color 0.2s ease; -webkit-transition: background-color 0.2s ease, border-color 0.2s ease; transition: background-color 0.2s ease, border-color 0.2s ease; border: none; color: #fff; margin: 0; padding: 10px 10px 7px 10px; border-radius: 0; text-decoration: none; font-family: Rubik, sans-serif; href/pipeline/alxn1840>ALXN1840/a> /div> /div> /div> /div> /div> /div> /div>/div>div classparallax-out wpb_row vc_row-fluid ihome-parallax overlay-light> div idsecond classupb_row_bg vcpb-hz-jquery stylebackground: url(https://d1io3yog0oux5.cloudfront.net/_70fd9f1ded729a9c8e504dca7e069527/monopartx/db/404/2686/background_image.jpg);background-position: 50% 50%;background-repeat: no-repeat;background-size: cover;background-color: #000;> div classcontainer> div classrow> div classcol-md-3 col-xs-12 col-sm-12>/div> div classcol-md-6 col-xs-12 col-sm-12 text-center no-pad heading-content wow fadeInUp animated animated data-wow-delay0.5s data-wow-offset200 stylevisibility: visible;-webkit-animation-delay: 0.5s; -moz-animation-delay: 0.5s; animation-delay: 0.5s;> div idheading-title2>Corporate Overview/div> p>Our management team has extensive experience in building companies and developing therapeutics through regulatory approval and commercialization. /p> div classalign_center>a href/investors classinner-page-butt-blue medium-but>Discover i classfa fa-angle-right aria-hiddentrue>/i>/a>/div> /div> div classcol-md-3 col-xs-12 col-sm-12>/div> /div> !--.story--> /div> /div> !--#second-->/div>!--divider-->div classpurchase-wrap-blue ipurchase-wrap> div classcontainer> div classrow> div classcol-xs-12 col-sm-12 col-md-12 pull-right> div classpurchase-strip-blue pull-right col-sm-12 col-md-12 col-xs-12 pull-left notViewed wow fadeInUp data-wow-delay0.5s data-wow-offset150> /div> /div> /div> /div>/div>!--divider-->div classcontainer> div classrow> !--Departments Start--> div classcol-xs-12 col-sm-12 col-md-12 pull-right department-wrap wow fadeInRight data-wow-delay0.5s data-wow-offset100 idresearch_pipeline_scrollto> div classcol-md-12 col-xs-12 col-sm-12 text-center no-pad heading-content heading-content2 wow fadeInUp animated animated data-wow-delay0.5s data-wow-offset200 stylevisibility: visible;-webkit-animation-delay: 0.5s; -moz-animation-delay: 0.5s; animation-delay: 0.5s;> div classcontent-headline> div idheading-title-pipeline>Our Research Pipeline/div> /div> p>span classnormaltextrun>span> /span>/span>/p>p>Monopars pipeline includes radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease. The radiopharma programs targeting advanced cancers include clinical-stage MNPR-101-Zr for imaging, and for therapy, clinical-stage MNPR-101-Lu and late-preclinical stage MNPR-101-Ac./p>p>br>br>span>/span>/p> /div> div classprogram> div classeq-container> div classpipeline-module> div classpipeline-row> div classrow> div classcol-md-12> table classpipeline-table> thead> tr> th>span classsr-only>Product/span>/th> th classindications>span classindication-span>Indications/span>/th> th classdiscovery>span>Discovery/span>/th> th classpreclinical>span>Preclinical/span>/th> th classphase-1>span>Phase 1/span>/th> th classphase-2>span>Phase 2/span>/th> th classphase-3>span>Phase 3/span>/th> th classindications>span classindication-span>Status/span>/th> /tr> /thead> tbody> tr classalxn1840-rare-disease> td> h4 classproduct> a href/pipeline/alxn1840> ALXN1840 (Rare Disease) /a> /h4> /td> td classindication> p classfor>Wilson Disease/p> /td> td classdiscovery candidate-phase data-phaseDiscovery> div classstatus complete> /div> p classphase-text>Discovery complete/p> /td> td classpreclinical candidate-phase data-phasePreclinical> div classstatus complete> /div> p classphase-text>Preclinical complete/p> /td> td classphase-1 candidate-phase data-phasePhase 1> div classstatus complete> /div> p classphase-text>Phase 1 complete/p> /td> td classphase-2 candidate-phase data-phasePhase 2> div classstatus complete> /div> p classphase-text>Phase 2 complete/p> /td> td classphase-3 candidate-phase current-phase data-phasePhase 3> div classstatus in-progress stylewidth:80%;> /div> p classphase-text>Phase 3 in progress/p> /td> td classstatus>Phase 3 Complete/td> /tr> tr classmnpr101zr-oncology> td> h4 classproduct> a href/pipeline/uPAR-targeted-radiopharmaceuticals> MNPR‑101‑Zr (Oncology) /a> /h4> /td> td classindication> p classfor>Advanced Solid Cancers (Imaging)/p> /td> td classdiscovery candidate-phase data-phaseDiscovery> div classstatus complete> /div> p classphase-text>Discovery complete/p> /td> td classpreclinical candidate-phase current-phase data-phasePreclinical> div classstatus in-progress stylewidth:110%;> /div> p classphase-text>Preclinical in progress/p> /td> td classphase-1 candidate-phase data-phasePhase 1> div classstatus not-started> /div> p classphase-text>Phase 1 not started/p> /td> td classphase-2 candidate-phase data-phasePhase 2> div classstatus not-started> /div> p classphase-text>Phase 2 not started/p> /td> td classphase-3 candidate-phase data-phasePhase 3> div classstatus not-started> /div> p classphase-text>Phase 3 not started/p> /td> td classstatus>Phase 1 Clinical Trial Active and Recruiting/td> /tr> tr classmnpr-101-lu-oncology> td> h4 classproduct> a href/pipeline/uPAR-targeted-radiopharmaceuticals> MNPR-101-Lu (Oncology) /a> /h4> /td> td classindication> p classfor>Advanced Solid Cancers/p> /td> td classdiscovery candidate-phase data-phaseDiscovery> div classstatus complete> /div> p classphase-text>Discovery complete/p> /td> td classpreclinical candidate-phase current-phase data-phasePreclinical> div classstatus in-progress stylewidth:100%;> /div> p classphase-text>Preclinical in progress/p> /td> td classphase-1 candidate-phase data-phasePhase 1> div classstatus not-started> /div> p classphase-text>Phase 1 not started/p> /td> td classphase-2 candidate-phase data-phasePhase 2> div classstatus not-started> /div> p classphase-text>Phase 2 not started/p> /td> td classphase-3 candidate-phase data-phasePhase 3> div classstatus not-started> /div> p classphase-text>Phase 3 not started/p> /td> td classstatus>Phase 1a Clinical Trial Active and Recruiting/td> /tr> tr classmnpr-101-ac-oncology> td> h4 classproduct> a href/pipeline/uPAR-targeted-radiopharmaceuticals> MNPR-101-Ac (Oncology) /a> /h4> /td> td classindication> p classfor>Advanced Solid Cancers/p> /td> td classdiscovery candidate-phase data-phaseDiscovery> div classstatus complete> /div> p classphase-text>Discovery complete/p> /td> td classpreclinical candidate-phase current-phase data-phasePreclinical> div classstatus in-progress stylewidth:85%;> /div> p classphase-text>Preclinical in progress/p> /td> td classphase-1 candidate-phase data-phasePhase 1> div classstatus not-started> /div> p classphase-text>Phase 1 not started/p> /td> td classphase-2 candidate-phase data-phasePhase 2> div classstatus not-started> /div> p classphase-text>Phase 2 not started/p> /td> td classphase-3 candidate-phase data-phasePhase 3> div classstatus not-started> /div> p classphase-text>Phase 3 not started/p> /td> td classstatus>Late Preclinical/td> /tr> /tbody> /table> /div> /div> /div>!--//pipeline-row--> /div>!--//pipeline-module--> /div> /div> /div> !--Departments End--> /div>/div>div classcontainer> div classrow> !--Departments Start--> div classcol-xs-12 col-sm-12 col-md-12 pull-right department-wrap wow fadeInRight data-wow-delay0.5s data-wow-offset100 idresearch_pipeline_scrollto> div classcol-md-12 col-xs-12 col-sm-12 text-center no-pad heading-content wow fadeInUp animated animated data-wow-delay0.5s data-wow-offset200 stylevisibility: visible;-webkit-animation-delay: 0.5s; -moz-animation-delay: 0.5s; animation-delay: 0.5s;> div classcontent-headline> div idheading-title-pipeline>Email Alerts/div> /div> p>Stay informed and receive company updates straight to your inbox/p> a hrefhttps://ir.monopartx.com/email-alerts classbtn inner-page-butt-blue medium-but sign-up-btn>Sign up today/a> /div> /div> !--Departments End--> /div>/div> /div> div classcomplete-footer> footer idfooter> div classcontainer> div classrow div-center> !--Foot widget--> div classcol-xs-12 col-sm-4 col-md-4 recent-post-foot foot-widget> ul> li>h5>About/h5>/li> li>a href/pipeline>Pipeline/a>/li> li>a href/investors>Investors/a>/li> li>a href/our-team>Our Team/a>/li> li>a href/careers>Careers/a>/li> li>a href/contact-us>Contact Us/a>/li> /ul> /div> div classcol-xs-12 col-sm-4 col-md-4 recent-post-foot foot-widget> ul> li> h5 classfooter-headings>a href/pipeline>Pipeline/a>/h5> /li> li>a href/pipeline/pipeline-chart>Pipeline Chart/a> li>a href/pipeline/alxn1840>ALXN1840/a> li>a href/pipeline/uPAR-targeted-radiopharmaceuticals>uPAR-targeted radiopharmaceuticals/a> li>a href/pipeline/mnpr-101>MNPR-101/a> li>a href/pipeline/collaborations>Collaborations/a> li>a href/pipeline/publications>Publications/a> /ul> /div> div classcol-xs-12 col-sm-4 col-md-4 recent-post-foot foot-widget> ul> li> h5 classfooter-headings>a href/investors>Investors/a>/h5> /li> li>a href/investors/_>Overview/a> li>a href/investors/annual-meeting>Annual Meeting/a> li>a href/investors/news-events>News / Events/a> li>a href/investors/company-information>Company Information/a> li>a href/investors/stock-data>Stock Data/a> li>a href/investors/sec-filings>SEC Filings/a> li>a href/investors/corporate-governance>Corporate Governance/a> /ul> /div> /div> /div> /footer> div classbottom-footer> div classcontainer> div classrow> !--Foot widget--> div classcol-xs-12 col-sm-12 col-md-12 foot-widget-bottom> p classcol-xs-12 col-md-12 no-pad text-center>a href/terms>Terms and Conditions of Use/a>/p> p classcol-xs-12 col-md-12 no-pad text-center>© 2026 a href/>Monopar Therapeutics Inc./a> All Rights Reserved. /p> /div> /div> /div> /div>/div>div classclear>/div>div classeq-container footer-container>/div>script> var asset_url https://d1io3yog0oux5.cloudfront.net/_70fd9f1ded729a9c8e504dca7e069527/monopartx; var website_base_url https://www.monopartx.com; var ir_base_url https://ir.monopartx.com; var hCaptchaSiteKey 778a5748-d323-4b73-a06c-9625642de8bc;/script> div classscript_block styledisplay: none> !--script srctemplate/imedica/HTML/js/jquery.min.js>/script> script srctemplate/imedica/HTML/js/jquery-ui-1.10.3.custom.min.js>/script> script srctemplate/imedica/HTML/bootstrap-new/js/bootstrap.min.js>/script> script srctemplate/imedica/HTML/rs-plugin/js/jquery.themepunch.tools.min.js>/script> script srctemplate/imedica/HTML/rs-plugin/js/jquery.themepunch.revolution.min.js>/script> script srctemplate/imedica/HTML/js/jquery.scrollUp.min.js>/script> script srctemplate/imedica/HTML/js/jquery.sticky.min.js>/script> script srctemplate/imedica/HTML/js/wow.min.js>/script> script srctemplate/imedica/HTML/js/jquery.flexisel.min.js>/script> script srctemplate/imedica/HTML/js/jquery.imedica.min.js>/script> script srctemplate/imedica/HTML/js/custom-imedicajs.min.js>/script>--> script srchttps://d1io3yog0oux5.cloudfront.net/_70fd9f1ded729a9c8e504dca7e069527/monopartx/files/theme/site-files/20180202/_js/vendor.min.js defer>/script> script srchttps://d1io3yog0oux5.cloudfront.net/_70fd9f1ded729a9c8e504dca7e069527/monopartx/files/theme/site-files/20180202/_js/innovate.min.js defer>/script> /div>script srchttps://d1io3yog0oux5.cloudfront.net/_70fd9f1ded729a9c8e504dca7e069527/monopartx/files/theme/js/_js/all.js>/script>/body>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]